Navigation Links
MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
Date:1/31/2008

VANCOUVER and SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI, OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, will add a 600mg celgosivir combination therapy arm to its currently enrolling Phase II viral kinetics study in hepatitis C virus ("HCV") treatment-naive patients. The protocol amendment to this study has received Health Canada and Institutional Review Board (IRB) approvals. The purpose of this new treatment arm is to assess 600mg celgosivir (an oral alpha glucosidase I inhibitor) for tolerability, pharmacokinetics and viral kinetics when combined with the standard of care drugs, pegylated interferon plus ribavirin, as compared to the standard of care drugs alone and to 400mg celgosivir plus the standard of care for up to 12 weeks of therapy.

AnnKatrin Petersen, M.D., VP Clinical Development for MIGENIX commented, "The favorable tolerability experienced to date with 400mg per day of celgosivir in triple combination with pegylated interferon plus ribavirin, along with the clinically significant benefit demonstrated in our previous non-responder study, gives us confidence that increasing the dose to 600mg per day in combination therapy is an important development step for the optimization and advancement of celgosivir."

The currently enrolling Phase II viral kinetics study is a 12-week randomized, active-controlled study initially planned to enroll up to 20 patients in two treatment arms: (i) celgosivir (400mg once daily) plus peginterferon alfa-2b plus ribavirin ("PRC"); and (ii) peginterferon alfa-2b plus ribavirin ("PR"). Tolerability, pharmacokinetics and viral kinetics are being evaluated in the trial. The approved protocol amendment allows for the addition of a 600mg once daily dosing arm and the flexibility to increase the total number of patients in the study up to 50. With 15 patients enrolled to date, it is planned that approximately six additional patients will be enrolled, all in th
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
2. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
3. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
5. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
6. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
7. Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
8. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
9. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
10. Phase 1 Studies Show Promise of QuatRxs Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
11. Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... -- Biostar,Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM) ("Biostar" or "the Company"),a Xianyang-based developer, ... and conditions,today announced fiscal results for its second quarter ended June 30, 2009. ... Results, ... Q2 2009 Q2 ...
... ... Web 2.0 Website in an effort to not only provide circuit board assembly and design ... ... value to their current and future customers Surface Mount Solutions (SMS) has launched a new ...
... , , , ... ACTC) announced today that Dr. Robert Lanza, its Chief Scientific Officer, is ... 102 and 55 [Live Saturday 12 pm - 1 pm ET; Replays ... The show focuses on Dr. Lanza,s research at ACTC and his new ...
Cached Biology Technology:Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 2Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 3Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 4Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 5Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 6Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 7Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 8Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 9Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 10Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 11Surface Mount Solutions Launches New Website 2Dr. Robert Lanza is Featured Guest on Deepak Chopra's SIRIUS XM Stars Radio Show 2Dr. Robert Lanza is Featured Guest on Deepak Chopra's SIRIUS XM Stars Radio Show 3
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to ... This accomplishment enables HITLAB to conduct regulated smart ... highest principles for patient safety and research quality. ... healthcare access, quality, and delivery with innovative technology," ...
(Date:12/17/2014)... -- Automation is fundamentally transforming the travel experience and ... borders. Over the past decade, ePassports, biometric readers, ... to self process through border control via eGates ... increasing number of airports, seaports, and land borders ... Maxine Most , Principal at Acuity Market ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... The way indigenous cultures around the globe use,traditional medicines ... linked to the,natural environment, new research has found. ... threat that comes on top of the challenges posed ... for more than half the world,s population, with 80 ...
... Energy,s (DOE,s) Office of Science and its labs will be ... AAAS Annual Meeting,CHICAGO Attendees of the 2014 AAAS Annual ... DOE,s Office of Science and its labs will play an ... President,s Address ,2014 AAAS co-chair ...
... PITTSBURGH, Feb. 13, 2014 University of Pittsburgh Cancer Institute ... to do new tricks., By screening a library of FDA-approved ... treatment for a rare type of cancer, UPCI scientists were ... the cancer becomes resistant to standard drug treatment., The discovery, ...
Cached Biology News:Environment change threatens indigenous know-how 2Department of Energy speakers and sessions at AAAS 2Department of Energy speakers and sessions at AAAS 3Department of Energy speakers and sessions at AAAS 4Department of Energy speakers and sessions at AAAS 5Department of Energy speakers and sessions at AAAS 6Laboratory detective work points to potential therapy for rare, drug-resistant cancer 2
For testing the AQUA technique on your MS instruments....
The Lambda Control Kit contains lambda DNA and two 25mer primers, which can be used to amplify a 500bp fragment. The lambda DNA is purified by CsCl gradient centrifugation and organic extraction foll...
A Highly Purified, Cost-Effective Taq DNA Polymerase...
...
Biology Products: